The safety and effect of human umbilical cord mesenchymal stem cells for the treatment of sepsis induced by pneumonia

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100050544

Enrollment

Unknown

Registered

2021-08-28

Start date

2021-09-01

Completion date

Unknown

Last updated

2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sepsis

Interventions

control group:Human umbilical cord mesenchymal stem cells transplantation

Experimental group:human umbilical cord mesenchymal stem cells transplantation

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Those who sign the informed consent form, the patients and their families have good compliance; 2. Inpatients aged 18 to 65 years (including both ends), male or female; 3. The diagnostic criteria are: according to the 2016 Sepsis 3.0 diagnostic criteria, namely infection and continuous sequential organ failure score (SOFA score) >= 2 points; 4. Survival time > 7 days; 5. The SOFA score of the patient is between 6-15.

Exclusion criteria

Exclusion criteria: 1. The patient's expected survival period is less than 7 days due to the presence of uncorrectable diseases, such as advanced tumors or other advanced diseases; 2. The patient is in a predictable moribund state; 3. HIV infection combined with the latest CD4 cell count <=50/mm3; 4. History of bone marrow, lung, liver, pancreas or small intestine transplantation; 5. Chronic renal failure requires hemodialysis or peritoneal dialysis; 6. Known or potential portal hypertension, chronic jaundice, chronic liver cirrhosis, ascites; 7. Severe liver failure (Child class C); 8. Volunteers who participated in other clinical trials within 30 days before the start of this trial; 9. Pregnant or lactating women; 10. Fungal sepsis; 11. The patient has a history of allergic reactions to biological products, hypersensitivity reactions or other serious reactions; 12. Long-term immunosuppressed patients; 13. Subjects deemed inappropriate by the investigator to participate in clinical research.

Design outcomes

Primary

Measure	Time frame
Serious adverse events;	—

Secondary

Measure	Time frame
Infection-related indicators;cytokine;cellular immunity;blood lactate;Blood biochemistry;Coagulation function;	—

Countries

China

Contacts

Public ContactTang Lunxian

Shanghai East Hospital (East Hospital Affiliated to Tongji University)

456tlx@163.com+86 18916290981

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 12, 2026